Shattuck advances SL-325 to Phase 2, raises $72M, extends cash runway to 2029

Filed May 7, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 1, 2025 · ~1 min read

Key Changes

• high

  Phase 1 trial nearing completion in Q2 2026 with Phase 2 initiation planned for Q3 2026 in Crohn's Disease patients, marking key de-risking milestone and first efficacy data catalyst.

  MD&A: Clinical Development verify on EDGAR →
• high

  Company raised $67M through August 2025 equity offering and Q1 2026 ATM sales at $4.28/share, extending cash runway from 2027 to 2029 and reducing near-term financing risk.

  MD&A: Capital Raises verify on EDGAR →
• medium

  Preclinical data now shows SL-325 receptor blockade lasts at least two months (doubled from one month), potentially enabling less frequent dosing versus TL1A competitors.

  MD&A: Durability Data verify on EDGAR →